Nutritional support for adult сystic fibrosis patients receiving targeted treatment-Reference-Cited by-同舟云学术

Nutritional support for adult сystic fibrosis patients receiving targeted treatment

Published:2024-03-14 Issue:2 Volume:34 Page:295-299
ISSN:2541-9617
Container-title:PULMONOLOGIYA
language:
Short-container-title:Pulʹmonologiâ (Mosk.)

Author:

Krylova N. A.¹^ORCID,Amelina E. L.¹^ORCID,Krasovsky S. A.²^ORCID,Shumkova G. L.¹^ORCID

Affiliation:

1. Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation

2. Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation; State Budgetary Healthcare Institution “City Clinical Hospital named after D.D.Pletnev of the Department of Health of Moscow City”

Abstract

Cystic fibrosis (CF) is characterized by the development of a severe nutritional deficiency. A low BMI directly correlates with low lung function and requires active nutritional support. Pathogenetic (targeted) therapy aimed at restoring the chlorine channel function also leads to weight gain. The effects of CFTR modulators on extrapulmonary pathology in adult CF patients in Russia have been described very little.Aim. To evaluate the sequential impact of two targeted drugs – the potentiator ivacaftor and the triple combination of CF transmembrane regulator modulators elexacaftor/tezacaftor/ivacaftor – on the nutritional status of an adult patient with cystic fibrosis receiving nutritional support.Conclusion. Therapy with CFTR modulator in combination with sipping nutritional support promotes significant weight gain in adult CF patients. The triple combination of elexacaftor/tezacaftor/ivacaftor has a more active effect on nutritional status than ivacaftor alone. The targeted therapy requires supervision by a nutritionist.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Reference15 articles.

1. Caley L.R., Jarosz-Griffiths H.H., Smith L. et al. Body mass index and nutritional intake following elexacaftor/tezacaftor/ivacaftor modulator therapy in adults with cystic fibrosis. J. Cyst. Fibros. 2023; 22 (6): 1002–1009. DOI: 10.1016/j.jcf2023.06.010.

2. Ooi C.Y., Durec. P.R. Cystic fibrosis from the gastroenterologist’s perspective. Nat. Rev. Gastroenterol. Hepatol. 2016; 13 (3): 175–185. DOI: 10.1038/ngastro.2015.226.

3. Stallings A., Stark L.J., Robinson K.A. et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J. Am Diet. Assoc. 2008; 108 (5): 832–839. DOI: 10.1016/j.jada.2008.02.020.

4. Cystic Fibrosis Trust. Nutritional management of cystic fibrosis. 2nd Edn. London; 2016. Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/Nutritional%20Management%20of%20cystic%20fibrosis%20Sep%2016.pdf

5. Bass R., Brownell J.N., Stallings V.A. The impact of highly effective CFTR modulators on growth and nutritional status. Nutrients. 2021; 13 (9): 2907. DOI: 10.3390/nu13092907.